Published in Arch Virol on January 01, 1982
Complete genome characterisation of a novel 26th bluetongue virus serotype from Kuwait. PLoS One (2011) 1.93
Umatilla virus genome sequencing and phylogenetic analysis: identification of stretch lagoon orbivirus as a new member of the Umatilla virus species. PLoS One (2011) 1.03
Full genome sequencing and genetic characterization of Eubenangee viruses identify Pata virus as a distinct species within the genus Orbivirus. PLoS One (2012) 0.93
Full genome sequencing of Corriparta virus, identifies California mosquito pool virus as a member of the Corriparta virus species. PLoS One (2013) 0.79
Genetic characterization of the tick-borne orbiviruses. Viruses (2015) 0.78
A New Orbivirus Isolated from Mosquitoes in North-Western Australia Shows Antigenic and Genetic Similarity to Corriparta Virus but Does Not Replicate in Vertebrate Cells. Viruses (2016) 0.78
Purification, stability, and immunogenicity analyses of five bluetongue virus proteins for use in development of a subunit vaccine that allows differentiation of infected from vaccinated animals. Clin Vaccine Immunol (2014) 0.77
Expression of VP7, a Bluetongue virus group specific antigen by viral vectors: analysis of the induced immune responses and evaluation of protective potential in sheep. PLoS One (2014) 0.76
Simple procedure for preparation of bluetongue virus and epizootic hemorrhagic disease virus antigens for agar gel immunodiffusion. J Clin Microbiol (1983) 0.75
Identification of the Genome Segments of Bluetongue Virus Serotype 26 (Isolate KUW2010/02) that Restrict Replication in a Culicoides sonorensis Cell Line (KC Cells). PLoS One (2016) 0.75
Full genome characterization of the culicoides-borne marsupial orbiviruses: Wallal virus, Mudjinbarry virus and Warrego viruses. PLoS One (2014) 0.75
Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc (1973) 13.43
Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature (1987) 5.26
Characterisation of a rotavirus.20b. Nature (1975) 2.21
Use of low concentrations of actinomycin D in the study of RNA synthesis in Ehrlich ascites cells. J Mol Biol (1966) 2.11
A physico-chemical sub-grouping of the mammalian picornaviruses. J Gen Virol (1973) 2.08
Further physicochemical characterization of Nodamura virus. Evidence that the divided genome occurs in a single component. J Gen Virol (1978) 1.78
Intra-cluster correlation coefficients of 20 infections calculated from the results of cluster-sample surveys. Prev Vet Med (1997) 1.52
Purification and identification of the RNA-dependent RNA polymerase of foot-and-mouth disease virus. J Gen Virol (1979) 1.50
In vitro translation of the Two RNAs of Nodamura virus, a novel mammalian virus with a divided genome. J Virol (1978) 1.49
Medical expenditures of terminal cancer patients during the last year of life. Inquiry (1984) 1.31
The airborne dispersal of foot-and-mouth disease virus from vaccinated and recovered pigs, cattle and sheep after exposure to infection. Res Vet Sci (1977) 1.29
The multiplication of Nodamura virus in insect and mammalian cell cultures. J Gen Virol (1975) 1.27
Clinical and serological response of sheep to serial challenge with different bluetongue virus types. Res Vet Sci (1983) 1.22
Absence of poly (A) from the infective RNA of Nodamura virus. J Gen Virol (1976) 1.18
Molecular weight of rhinovirus ribonucleic acid. J Gen Virol (1970) 1.17
Oligonucleotide mapping of picornavirus RNAs by two-dimensional electrophoresis. Virology (1976) 1.16
Serological survey of ruminants in some Caribbean and South American countries for type-specific antibody to bluetongue and epizootic haemorrhagic disease viruses. Vet Rec (1984) 1.12
Bluetongue epidemiology in the Middle East. Prog Clin Biol Res (1985) 0.96
How older adults use oral health care services: results of a National Health Interview Survey. J Am Dent Assoc (1993) 0.96
Physicochemical characterization of two serologically unrelated equine rhinoviruses. Intervirology (1977) 0.94
A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies. Proc Natl Acad Sci U S A (1997) 0.91
Oral health activities of U.S. children: results of a national health interview survey. J Am Dent Assoc (1992) 0.90
Baculovirus expressed 2C of foot-and-mouth disease virus has the potential for differentiating convalescent from vaccinated animals. J Virol Methods (1997) 0.89
Inhibition of the uncoating of bovine enterovirus by short chain fatty acids. J Gen Virol (1990) 0.88
Synthesis of Maus-Elberfeld viral RNA in ascites tumor cells. J Mol Biol (1966) 0.88
Attempts to control dental health care costs: the U.S. experience. Soc Sci Med A (1981) 0.88
Characterization of an acid-resistant mutant of foot-and-mouth disease virus. Virology (1995) 0.86
Isolation of bovine herpesvirus-3 from African buffaloes (Syncerus caffer). Res Vet Sci (1989) 0.85
Induced ribonucleic acids in cells infected with vesicular stomatitis virus. J Gen Virol (1969) 0.84
Bluetongue in exotic sheep in Cameroon. Trop Anim Health Prod (1985) 0.84
The growth of cell culture-attenuated rinderpest virus in bovine lymphoblasts with B cell, CD4+ and CD8+ alpha/beta T cell and gamma/delta T cell phenotypes. J Gen Virol (1993) 0.81
The use of serology in bluetongue epidemiology. Prog Clin Biol Res (1985) 0.80
A universal virus inactivant for decontaminating blood and biopharmaceutical products. Dev Biol Stand (1999) 0.80
Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of foot-and-mouth disease virus VP1 which does not contain the RGD motif. Vaccine (1999) 0.80
Absence of protein 2C from clarified foot-and-mouth disease virus vaccines provides the basis for distinguishing convalescent from vaccinated animals. Vaccine (1996) 0.80
A universal virus inactivant for decontaminating blood and biopharmaceutical products. Biologicals (1998) 0.80
The cost of poor birth outcomes in employer-sponsored health plans. Med Care (1996) 0.80
Endopeptidase variations among different life-cycle stages of African trypanosomes. Eur J Biochem (1991) 0.80
Is the AGID test group-specific for epizootic haemorrhagic disease virus? Prog Clin Biol Res (1985) 0.79
A drug incubation infectivity test (DIIT) for assessing resistance in trypanosomes. Vet Parasitol (1990) 0.79
Antigenic variants in a plaque-isolate of foot-and-mouth disease virus: implications for vaccine production. Vaccine (1995) 0.79
Monitoring quality of nursing care. Health Serv Res (1974) 0.78
The decline in the Blue Cross Plan admission rate: four explanations. Inquiry (1983) 0.78
In vitro development of metacyclic Trypanosoma simiae derived from bloodstream trypomastigotes. Acta Trop (1989) 0.77
Immunological relationships between malignant catarrhal fever virus (alcelaphine herpesvirus 1) and bovine cytomegalovirus (bovine herpesvirus 3). Vet Microbiol (1988) 0.77
Characterisation of a cysteine protease from bloodstream forms of Trypanosoma congolense. Eur J Biochem (1992) 0.77
Differentiating foot-and-mouth disease virus-infected from vaccinated animals with baculovirus-expressed specific proteins. Vet Q (1998) 0.76
Circular dichroism, molecular modeling, and serology indicate that the structural basis of antigenic variation in foot-and-mouth disease virus is alpha-helix formation. Proc Natl Acad Sci U S A (1994) 0.75
The Hospital Capitation Payment Project: new incentives and tools for cost containment. Inquiry (1983) 0.75
The Providence Plan: prepaid health care for a voluntarily enrolled population. Inquiry (1983) 0.75
Prevalence of bluetongue virus and antibodies in ruminants in Cameroon. Trop Anim Health Prod (1985) 0.75
Polymerized serum albumin beads possessing slow release properties for use in vaccines. Vaccine (1988) 0.75
Growth of rinderpest and bovine virus diarrhoea viruses in Theileria parva infected lymphoblastoid cell lines. Vet Rec (1988) 0.75
Attempts of control health care costs: the United States experience. Soc Sci Med (1979) 0.75
Biodegradable serum albumin polymers for the sustained release of virus antigens in vaccines. A preliminary report. S Afr Med J (1984) 0.75
Antibody response to bacterial antigens covalently bound to biodegradable polymerized serum albumin beads. J Appl Bacteriol (1987) 0.75
Essential competencies in human resource management. J Health Adm Educ (2001) 0.75
Continuing presence of rinderpest virus as a threat in East Africa, 1983-1985. Vet Rec (1987) 0.75
Use of Vero cells for the isolation and propagation of malignant catarrhal fever virus. Trop Anim Health Prod (1987) 0.75
Peptide mapping of the group-specific antigens from the Australian bluetongue virus (BTV-20) and serotypes from southern Africa and North America. Vet Microbiol (1986) 0.75
Three is the magic number. Br Med J (Clin Res Ed) (1982) 0.75
Experience with retrospective medical audit in ambulatory care. Mil Med (1978) 0.75